| Lower Brule Indian Health Service | |
|
601 Gall Street Lower Brule SD 57548-0248 | |
| (605) 473-5526 | |
| (605) 473-0828 |
| Full Name | Lower Brule Indian Health Service |
|---|---|
| Speciality | Clinic/Center |
| Location | 601 Gall Street, Lower Brule, South Dakota |
| Authorized Official Name and Position | Eyvonne T Rekow (CHIEF EXECUTIVE OFFICER) |
| Authorized Official Contact | 6054735526 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Lower Brule Indian Health Service Po Box 248 601 Gall Street Lower Brule SD 57548-0248 Ph: (605) 473-5526 | Lower Brule Indian Health Service 601 Gall Street Lower Brule SD 57548-0248 Ph: (605) 473-5526 |
| NPI Number | 1881719425 |
|---|---|
| Provider Enumeration Date | 03/20/2007 |
| Last Update Date | 12/22/2016 |
| Medicare PECOS PAC ID | 8224023585 |
|---|---|
| Medicare Enrollment ID | O20040423001291 |
News Archive
A gene that can cause congenital heart defects has been identified by a team of scientists, including a group from Princeton University. The discovery could lead to new treatments for those affected by the conditions brought on by the birth defect.
Researchers at the Max Delbrueck Center for Molecular Medicine have identified an epigenetic mechanism that appears to strongly influence healthy aging.
The role of microRNAs is fundamental for the correct moment-to-moment adjustment in the expression of target genes. "Before this study, we already knew that these small molecules could be packaged into small vesicles and exported to the extracellular space, to be later captured by other cells and in this way play an important role in intercellular communication," explains CNIC researcher Carolina Villarroya, the first author on the study.
Eisai announced today that the company received a Complete Response Letter from the United States Food and Drug Administration (FDA) regarding the New Drug Application (NDA) of rabeprazole sodium extended-release capsules, 50 mg, an investigational proton pump inhibitor (PPI) under review for the healing and long-term maintenance of healing and symptom resolution of erosive gastroesophageal reflux disease (GERD), and for the treatment of daytime and nighttime heartburn and other symptoms of non-erosive GERD.
Components in the outer wall of bacteria directly activate pain sensors, triggering immediate pain and inflammatory responses. This finding by a multinational team of researchers led by Professor Karel Talavera (KU Leuven, Belgium) and Professor Félix Viana (Institute of Neuroscience, Spain) sheds new light on pain associated with bacterial infections and reveals a new target for drugs designed to treat them.
› Verified 7 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1881719425 | NPI | - | NPPES |
| 4304882 | Other | SD | NABP |
| 5549020 | Medicaid | SD | |
| HSZ133 | Other | SD | MEDICARE INDENTIFIER |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261Q00000X | Clinic/center | (South Dakota) | Primary |
| Provider Name | George J Ceremuga |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1760445613 PECOS PAC ID: 6204720824 Enrollment ID: I20041008000552 |
News Archive
A gene that can cause congenital heart defects has been identified by a team of scientists, including a group from Princeton University. The discovery could lead to new treatments for those affected by the conditions brought on by the birth defect.
Researchers at the Max Delbrueck Center for Molecular Medicine have identified an epigenetic mechanism that appears to strongly influence healthy aging.
The role of microRNAs is fundamental for the correct moment-to-moment adjustment in the expression of target genes. "Before this study, we already knew that these small molecules could be packaged into small vesicles and exported to the extracellular space, to be later captured by other cells and in this way play an important role in intercellular communication," explains CNIC researcher Carolina Villarroya, the first author on the study.
Eisai announced today that the company received a Complete Response Letter from the United States Food and Drug Administration (FDA) regarding the New Drug Application (NDA) of rabeprazole sodium extended-release capsules, 50 mg, an investigational proton pump inhibitor (PPI) under review for the healing and long-term maintenance of healing and symptom resolution of erosive gastroesophageal reflux disease (GERD), and for the treatment of daytime and nighttime heartburn and other symptoms of non-erosive GERD.
Components in the outer wall of bacteria directly activate pain sensors, triggering immediate pain and inflammatory responses. This finding by a multinational team of researchers led by Professor Karel Talavera (KU Leuven, Belgium) and Professor Félix Viana (Institute of Neuroscience, Spain) sheds new light on pain associated with bacterial infections and reveals a new target for drugs designed to treat them.
› Verified 7 days ago
| Provider Name | Leann K Batiz |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1356684492 PECOS PAC ID: 0749429835 Enrollment ID: I20140903000475 |
News Archive
A gene that can cause congenital heart defects has been identified by a team of scientists, including a group from Princeton University. The discovery could lead to new treatments for those affected by the conditions brought on by the birth defect.
Researchers at the Max Delbrueck Center for Molecular Medicine have identified an epigenetic mechanism that appears to strongly influence healthy aging.
The role of microRNAs is fundamental for the correct moment-to-moment adjustment in the expression of target genes. "Before this study, we already knew that these small molecules could be packaged into small vesicles and exported to the extracellular space, to be later captured by other cells and in this way play an important role in intercellular communication," explains CNIC researcher Carolina Villarroya, the first author on the study.
Eisai announced today that the company received a Complete Response Letter from the United States Food and Drug Administration (FDA) regarding the New Drug Application (NDA) of rabeprazole sodium extended-release capsules, 50 mg, an investigational proton pump inhibitor (PPI) under review for the healing and long-term maintenance of healing and symptom resolution of erosive gastroesophageal reflux disease (GERD), and for the treatment of daytime and nighttime heartburn and other symptoms of non-erosive GERD.
Components in the outer wall of bacteria directly activate pain sensors, triggering immediate pain and inflammatory responses. This finding by a multinational team of researchers led by Professor Karel Talavera (KU Leuven, Belgium) and Professor Félix Viana (Institute of Neuroscience, Spain) sheds new light on pain associated with bacterial infections and reveals a new target for drugs designed to treat them.
› Verified 7 days ago
| Provider Name | Cassandra A Gutzmer |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1215285093 PECOS PAC ID: 4789835265 Enrollment ID: I20150220000814 |
News Archive
A gene that can cause congenital heart defects has been identified by a team of scientists, including a group from Princeton University. The discovery could lead to new treatments for those affected by the conditions brought on by the birth defect.
Researchers at the Max Delbrueck Center for Molecular Medicine have identified an epigenetic mechanism that appears to strongly influence healthy aging.
The role of microRNAs is fundamental for the correct moment-to-moment adjustment in the expression of target genes. "Before this study, we already knew that these small molecules could be packaged into small vesicles and exported to the extracellular space, to be later captured by other cells and in this way play an important role in intercellular communication," explains CNIC researcher Carolina Villarroya, the first author on the study.
Eisai announced today that the company received a Complete Response Letter from the United States Food and Drug Administration (FDA) regarding the New Drug Application (NDA) of rabeprazole sodium extended-release capsules, 50 mg, an investigational proton pump inhibitor (PPI) under review for the healing and long-term maintenance of healing and symptom resolution of erosive gastroesophageal reflux disease (GERD), and for the treatment of daytime and nighttime heartburn and other symptoms of non-erosive GERD.
Components in the outer wall of bacteria directly activate pain sensors, triggering immediate pain and inflammatory responses. This finding by a multinational team of researchers led by Professor Karel Talavera (KU Leuven, Belgium) and Professor Félix Viana (Institute of Neuroscience, Spain) sheds new light on pain associated with bacterial infections and reveals a new target for drugs designed to treat them.
› Verified 7 days ago
| Provider Name | Urooj Saeed |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1710272588 PECOS PAC ID: 2163732801 Enrollment ID: I20151109000254 |
News Archive
A gene that can cause congenital heart defects has been identified by a team of scientists, including a group from Princeton University. The discovery could lead to new treatments for those affected by the conditions brought on by the birth defect.
Researchers at the Max Delbrueck Center for Molecular Medicine have identified an epigenetic mechanism that appears to strongly influence healthy aging.
The role of microRNAs is fundamental for the correct moment-to-moment adjustment in the expression of target genes. "Before this study, we already knew that these small molecules could be packaged into small vesicles and exported to the extracellular space, to be later captured by other cells and in this way play an important role in intercellular communication," explains CNIC researcher Carolina Villarroya, the first author on the study.
Eisai announced today that the company received a Complete Response Letter from the United States Food and Drug Administration (FDA) regarding the New Drug Application (NDA) of rabeprazole sodium extended-release capsules, 50 mg, an investigational proton pump inhibitor (PPI) under review for the healing and long-term maintenance of healing and symptom resolution of erosive gastroesophageal reflux disease (GERD), and for the treatment of daytime and nighttime heartburn and other symptoms of non-erosive GERD.
Components in the outer wall of bacteria directly activate pain sensors, triggering immediate pain and inflammatory responses. This finding by a multinational team of researchers led by Professor Karel Talavera (KU Leuven, Belgium) and Professor Félix Viana (Institute of Neuroscience, Spain) sheds new light on pain associated with bacterial infections and reveals a new target for drugs designed to treat them.
› Verified 7 days ago
| Provider Name | Thuy-trang T Ngo |
|---|---|
| Provider Type | Practitioner - Nephrology |
| Provider Identifiers | NPI Number: 1831327444 PECOS PAC ID: 5698990075 Enrollment ID: I20180109002084 |
News Archive
A gene that can cause congenital heart defects has been identified by a team of scientists, including a group from Princeton University. The discovery could lead to new treatments for those affected by the conditions brought on by the birth defect.
Researchers at the Max Delbrueck Center for Molecular Medicine have identified an epigenetic mechanism that appears to strongly influence healthy aging.
The role of microRNAs is fundamental for the correct moment-to-moment adjustment in the expression of target genes. "Before this study, we already knew that these small molecules could be packaged into small vesicles and exported to the extracellular space, to be later captured by other cells and in this way play an important role in intercellular communication," explains CNIC researcher Carolina Villarroya, the first author on the study.
Eisai announced today that the company received a Complete Response Letter from the United States Food and Drug Administration (FDA) regarding the New Drug Application (NDA) of rabeprazole sodium extended-release capsules, 50 mg, an investigational proton pump inhibitor (PPI) under review for the healing and long-term maintenance of healing and symptom resolution of erosive gastroesophageal reflux disease (GERD), and for the treatment of daytime and nighttime heartburn and other symptoms of non-erosive GERD.
Components in the outer wall of bacteria directly activate pain sensors, triggering immediate pain and inflammatory responses. This finding by a multinational team of researchers led by Professor Karel Talavera (KU Leuven, Belgium) and Professor Félix Viana (Institute of Neuroscience, Spain) sheds new light on pain associated with bacterial infections and reveals a new target for drugs designed to treat them.
› Verified 7 days ago
| Provider Name | Janell L Simpkins |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1619989605 PECOS PAC ID: 6204025661 Enrollment ID: I20180308000855 |
News Archive
A gene that can cause congenital heart defects has been identified by a team of scientists, including a group from Princeton University. The discovery could lead to new treatments for those affected by the conditions brought on by the birth defect.
Researchers at the Max Delbrueck Center for Molecular Medicine have identified an epigenetic mechanism that appears to strongly influence healthy aging.
The role of microRNAs is fundamental for the correct moment-to-moment adjustment in the expression of target genes. "Before this study, we already knew that these small molecules could be packaged into small vesicles and exported to the extracellular space, to be later captured by other cells and in this way play an important role in intercellular communication," explains CNIC researcher Carolina Villarroya, the first author on the study.
Eisai announced today that the company received a Complete Response Letter from the United States Food and Drug Administration (FDA) regarding the New Drug Application (NDA) of rabeprazole sodium extended-release capsules, 50 mg, an investigational proton pump inhibitor (PPI) under review for the healing and long-term maintenance of healing and symptom resolution of erosive gastroesophageal reflux disease (GERD), and for the treatment of daytime and nighttime heartburn and other symptoms of non-erosive GERD.
Components in the outer wall of bacteria directly activate pain sensors, triggering immediate pain and inflammatory responses. This finding by a multinational team of researchers led by Professor Karel Talavera (KU Leuven, Belgium) and Professor Félix Viana (Institute of Neuroscience, Spain) sheds new light on pain associated with bacterial infections and reveals a new target for drugs designed to treat them.
› Verified 7 days ago
| Provider Name | Seth A Mandel |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1255444022 PECOS PAC ID: 4688671209 Enrollment ID: I20190626002493 |
News Archive
A gene that can cause congenital heart defects has been identified by a team of scientists, including a group from Princeton University. The discovery could lead to new treatments for those affected by the conditions brought on by the birth defect.
Researchers at the Max Delbrueck Center for Molecular Medicine have identified an epigenetic mechanism that appears to strongly influence healthy aging.
The role of microRNAs is fundamental for the correct moment-to-moment adjustment in the expression of target genes. "Before this study, we already knew that these small molecules could be packaged into small vesicles and exported to the extracellular space, to be later captured by other cells and in this way play an important role in intercellular communication," explains CNIC researcher Carolina Villarroya, the first author on the study.
Eisai announced today that the company received a Complete Response Letter from the United States Food and Drug Administration (FDA) regarding the New Drug Application (NDA) of rabeprazole sodium extended-release capsules, 50 mg, an investigational proton pump inhibitor (PPI) under review for the healing and long-term maintenance of healing and symptom resolution of erosive gastroesophageal reflux disease (GERD), and for the treatment of daytime and nighttime heartburn and other symptoms of non-erosive GERD.
Components in the outer wall of bacteria directly activate pain sensors, triggering immediate pain and inflammatory responses. This finding by a multinational team of researchers led by Professor Karel Talavera (KU Leuven, Belgium) and Professor Félix Viana (Institute of Neuroscience, Spain) sheds new light on pain associated with bacterial infections and reveals a new target for drugs designed to treat them.
› Verified 7 days ago
| Provider Name | Alyssa Mae Welbig |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1356851661 PECOS PAC ID: 5597025874 Enrollment ID: I20191028000022 |
News Archive
A gene that can cause congenital heart defects has been identified by a team of scientists, including a group from Princeton University. The discovery could lead to new treatments for those affected by the conditions brought on by the birth defect.
Researchers at the Max Delbrueck Center for Molecular Medicine have identified an epigenetic mechanism that appears to strongly influence healthy aging.
The role of microRNAs is fundamental for the correct moment-to-moment adjustment in the expression of target genes. "Before this study, we already knew that these small molecules could be packaged into small vesicles and exported to the extracellular space, to be later captured by other cells and in this way play an important role in intercellular communication," explains CNIC researcher Carolina Villarroya, the first author on the study.
Eisai announced today that the company received a Complete Response Letter from the United States Food and Drug Administration (FDA) regarding the New Drug Application (NDA) of rabeprazole sodium extended-release capsules, 50 mg, an investigational proton pump inhibitor (PPI) under review for the healing and long-term maintenance of healing and symptom resolution of erosive gastroesophageal reflux disease (GERD), and for the treatment of daytime and nighttime heartburn and other symptoms of non-erosive GERD.
Components in the outer wall of bacteria directly activate pain sensors, triggering immediate pain and inflammatory responses. This finding by a multinational team of researchers led by Professor Karel Talavera (KU Leuven, Belgium) and Professor Félix Viana (Institute of Neuroscience, Spain) sheds new light on pain associated with bacterial infections and reveals a new target for drugs designed to treat them.
› Verified 7 days ago
| Provider Name | Adam Peterson |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1033539937 PECOS PAC ID: 9436378734 Enrollment ID: I20200406003274 |
News Archive
A gene that can cause congenital heart defects has been identified by a team of scientists, including a group from Princeton University. The discovery could lead to new treatments for those affected by the conditions brought on by the birth defect.
Researchers at the Max Delbrueck Center for Molecular Medicine have identified an epigenetic mechanism that appears to strongly influence healthy aging.
The role of microRNAs is fundamental for the correct moment-to-moment adjustment in the expression of target genes. "Before this study, we already knew that these small molecules could be packaged into small vesicles and exported to the extracellular space, to be later captured by other cells and in this way play an important role in intercellular communication," explains CNIC researcher Carolina Villarroya, the first author on the study.
Eisai announced today that the company received a Complete Response Letter from the United States Food and Drug Administration (FDA) regarding the New Drug Application (NDA) of rabeprazole sodium extended-release capsules, 50 mg, an investigational proton pump inhibitor (PPI) under review for the healing and long-term maintenance of healing and symptom resolution of erosive gastroesophageal reflux disease (GERD), and for the treatment of daytime and nighttime heartburn and other symptoms of non-erosive GERD.
Components in the outer wall of bacteria directly activate pain sensors, triggering immediate pain and inflammatory responses. This finding by a multinational team of researchers led by Professor Karel Talavera (KU Leuven, Belgium) and Professor Félix Viana (Institute of Neuroscience, Spain) sheds new light on pain associated with bacterial infections and reveals a new target for drugs designed to treat them.
› Verified 7 days ago
| Provider Name | John D Nguyen |
|---|---|
| Provider Type | Practitioner - General Practice |
| Provider Identifiers | NPI Number: 1306078522 PECOS PAC ID: 8729116819 Enrollment ID: I20220427001157 |
News Archive
A gene that can cause congenital heart defects has been identified by a team of scientists, including a group from Princeton University. The discovery could lead to new treatments for those affected by the conditions brought on by the birth defect.
Researchers at the Max Delbrueck Center for Molecular Medicine have identified an epigenetic mechanism that appears to strongly influence healthy aging.
The role of microRNAs is fundamental for the correct moment-to-moment adjustment in the expression of target genes. "Before this study, we already knew that these small molecules could be packaged into small vesicles and exported to the extracellular space, to be later captured by other cells and in this way play an important role in intercellular communication," explains CNIC researcher Carolina Villarroya, the first author on the study.
Eisai announced today that the company received a Complete Response Letter from the United States Food and Drug Administration (FDA) regarding the New Drug Application (NDA) of rabeprazole sodium extended-release capsules, 50 mg, an investigational proton pump inhibitor (PPI) under review for the healing and long-term maintenance of healing and symptom resolution of erosive gastroesophageal reflux disease (GERD), and for the treatment of daytime and nighttime heartburn and other symptoms of non-erosive GERD.
Components in the outer wall of bacteria directly activate pain sensors, triggering immediate pain and inflammatory responses. This finding by a multinational team of researchers led by Professor Karel Talavera (KU Leuven, Belgium) and Professor Félix Viana (Institute of Neuroscience, Spain) sheds new light on pain associated with bacterial infections and reveals a new target for drugs designed to treat them.
› Verified 7 days ago
News Archive
A gene that can cause congenital heart defects has been identified by a team of scientists, including a group from Princeton University. The discovery could lead to new treatments for those affected by the conditions brought on by the birth defect.
Researchers at the Max Delbrueck Center for Molecular Medicine have identified an epigenetic mechanism that appears to strongly influence healthy aging.
The role of microRNAs is fundamental for the correct moment-to-moment adjustment in the expression of target genes. "Before this study, we already knew that these small molecules could be packaged into small vesicles and exported to the extracellular space, to be later captured by other cells and in this way play an important role in intercellular communication," explains CNIC researcher Carolina Villarroya, the first author on the study.
Eisai announced today that the company received a Complete Response Letter from the United States Food and Drug Administration (FDA) regarding the New Drug Application (NDA) of rabeprazole sodium extended-release capsules, 50 mg, an investigational proton pump inhibitor (PPI) under review for the healing and long-term maintenance of healing and symptom resolution of erosive gastroesophageal reflux disease (GERD), and for the treatment of daytime and nighttime heartburn and other symptoms of non-erosive GERD.
Components in the outer wall of bacteria directly activate pain sensors, triggering immediate pain and inflammatory responses. This finding by a multinational team of researchers led by Professor Karel Talavera (KU Leuven, Belgium) and Professor Félix Viana (Institute of Neuroscience, Spain) sheds new light on pain associated with bacterial infections and reveals a new target for drugs designed to treat them.
› Verified 7 days ago
Indian Health Services Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 601 Gall St, Lower Brule, SD 57548 Phone: 309-363-2711 |